The recommendations are similar to those recently announced for TTVR, with the final NCD for T-TEER expected by July.

At two years of follow-up, patients with a poorly functioning tricuspid valve in the heart who received the best available ...

Champions of tricuspid transcatheter edge-to-edge repair (TEER) were buoyed by 2-year results of the TRILUMINATE trial ...

Ben McCullough, 76, received an EVOQUE heart valve last fall. On Wednesday, he got to thank the makers face-to-face.

Here are the biggest stories out of ACC 2025: Five-year data from the Medtronic Evolut Low Risk Trial confirmed that its ...

Medtronic, Abbott and Boston Scientific provided updates on their devices used in heart valve disease treatment at the event.

Ben McCullough met the 25 Edwards Lifesciences technicians who spent 20 hours hand-sewing 2,000 stitches to make a valve ...

Abbott (NYSE: ABT) today announced data demonstrating substantial, sustained improvements with its TriClip system.

Abbott (NYSE: ABT) today announced late-breaking data from its TRILUMINATE™ Pivotal trial that show the TriClip™ transcatheter edge-to-edge repair (TEER) system to treat tricuspid regurgitation (TR), ...

The tricuspid valve, one of four valves in the heart, controls blood flow from the right atrium (the heart’s upper-right chamber) to the right ventricle (the lower-right chamber).